MgShell manufactures intraocular devices for treating exudative form of age-related macular degeneration.
MgShell has raised $1.3M in total funding. The most recent round was Seed. The last funding was announced in April 2025.
MgShell's investors include Capital Cell, Club degli Investitori, Simon Fiduciaria, PoliHub, Italian Angels for Biotech.
MgShell is headquartered in Milan, Italy.
MgShell manufactures intraocular devices for treating exudative form of age-related macular degeneration.
MgShell is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MgShell — Funding & Investors." VCBacked, April 30, 2025, https://www.vcbacked.co/company/mgshell. Accessed September 29, 2026.
VCBacked. (2025). MgShell — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/mgshell
{{cite web |title=MgShell — Funding & Investors |url=https://www.vcbacked.co/company/mgshell |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated